FOUNTAIN VALLEY, CA -- (MARKET WIRE) -- May 11, 2007 -- Alpine Biomed is pleased to announce the acquisition of Medtronic's gastroenterology diagnostic product line. The transaction closed today, and transfers worldwide ownership of the product line to Alpine Biomed. Alpine Biomed has been the U.S. distributor of the product line for the last year.
Under the terms of the acquisition, Alpine Biomed assumes all aspects of sales, marketing, distribution, service, customer support and product development. Included in the deal are gastro diagnostic equipment including Digitrapper™ 400 pH recorder, Polygraf™ ID multi-parametric recorder for pH and manometry, and a license to the POLYGRAM NET® software. The acquired products complement Alpine's extensive line of VersaFlex™ and GeroFlex™ pH and impedance catheters for esophageal diagnostic testing. Medtronic's Bravo® pH monitoring system -- used to diagnose gastroesophageal reflux disease (GERD) -- is not included in the acquisition and will continue to be sold and supported by Medtronic.
"We are excited to incorporate these fine Medtronic products into the Alpine family, and we look forward to working closely with our customers to continually improve on our excellent product quality and customer support," said Brad Westcott, President of Alpine Biomed.
Alpine will be exhibiting at the upcoming Digestive Disease Week show in Washington, D.C., May 20-23, and the Society for Gastroenterology Nurses and Associates 34th Annual Course in Baltimore May 20-22.
Established in 1994 and ISO 13485 certified, Alpine Biomed manufactures and distributes intelligent diagnostic tools for use in gastroenterology and neurology. Alpine Biomed is driven to supply reliable diagnostic medical devices within a positive working environment that benefit both patient and clinician.
For further information contact William Brown, Chief Operating Officer, Alpine Biomed Corp., 714-839-8426.
Chief Operating Officer
Alpine Biomed Corp.
17800 Newhope St., Ste B
Fountain Valley, CA 92708
SOURCE: Alpine Biomed Corp.
>>> Discuss This Story